Latest News

To perform a propensity-score matched analysis comparing SBRT boost and HDR boost for localized prostate cancer. A single-institution retrospective chart review was conducted of men treated with pelvic external beam radiotherapy (EBRT) and SBRT boost (21Gy/19Gy in 2 fractions) to the prostate for prostate cancer.

To develop a simplified MRI-based model to predict the risk for positive surgical margins (PSMs) after radical prostatectomy (RP) in patients with prostate cancer (PCa). Consecutive patients who underwent RP for PCa were retrospectively identified from a tertiary referral hospital.

The salvage treatments for biochemical recurrence (BCR) include local external beam radiation therapy (RT) and systemic androgen-deprivation therapy (ADT). We reviewed patients who underwent radical prostatectomy (RP) and developed BCR at three institutions.

Lichen sclerosus (LS) is a rare disease with malignant potential and has been identified by the European Society of Urology Guidelines as a risk factor for penile squamous cell carcinoma (SCC) cancer.

Peptide drugs provide promising regimes in bladder cancer. In order to identify potential bioactive peptides involved in bladder cancer, we performed the present study. Liquid chromatography/mass spectrometry assay was used to compare the endogenous peptides between bladder cancer and normal control.

Non-muscle-invasive bladder cancer (NMIBC) is characterized by frequent recurrence of the disease, which is difficult to predict. To combine digital histopathology slides with clinical data to predict 1- and 5-yr recurrence-free survival of NMIBC patients using deep learning.

The malignant transformation of normal bladder cells (SV-HUC-1) was induced by arsenite to explore the possible mechanism of circRNA-100284 influencing bladder cancer cell proliferation. Normal bladder SV-HUC-1 cells were cultured with 2 μM arsenite to induce malignant transformation.

To assess the trends of neoadjuvant chemotherapy (NAC) use since its introduction in our practice pathway in patients with cT2 + bladder cancer over a 20-year period. This is a retrospective review of patients with cT2 + bladder cancer who underwent RC between 01/01/1998 and 01/01/2018 that aimed to evaluate the trends of NAC use and associated after implementation […]

{{header-clinical-trials-navigation}} Prostate Cancer Biomarker Enrichment and Treatment Selection (PC-BETS) Study Condition: Prostate Cancer Study Type: Interventional Clinical Trials Identifier NCT 8-digits: NCT03385655 Sponsor: Canadian Cancer Trials Group Phase: Phase 2 Eligibility: Age: minimum 18 Years maximum N/A Gender: Male Inclusion Criteria: The following will be required prior to REGISTRATION: Patients must have histologically confirmed adenocarcinoma […]

GEMTESA is the first new oral branded OAB medication approved by the U.S. FDA since 2012 and the first product approval for Urovant Sciences U.S. commercial launch planned in late-Q1 2021 San Francisco, CA (UroToday.com) — Urovant Sciences announced that the U.S. Food and Drug Administration (FDA) has approved the New Drug Application (NDA) for once-daily 75 mg GEMTESA® […]